Page 613«..1020..612613614615..620630..»

NeoStem Reports Data Safety Monitoring Board Recommends Continuation of PreSERVE AMI Phase 2 Trial

By daniellenierenberg

NEW YORK, Aug. 15, 2012 (GLOBE NEWSWIRE) -- Amorcyte, a company of NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a rapidly emerging market leader in the fast growing cell therapy market, today announced that it received on August 9, 2012 approval to continue its PreSERVE AMI Phase 2 clinical trial following its first interim data and safety review by the Data Safety Monitoring Board (DSMB). The PreSERVE trial is a Phase 2, randomized, placebo controlled, double-blind study expected to include 160 patients at more than 40 clinical sites. The trial's product candidate, AMR-001, is designed to prevent major adverse cardiac events following acute myocardial infarction (AMI). Patient enrollment for the PreSERVE trial began in January 2012 and the Company anticipates completing enrollment in 2013 with six months initial data readout near the end of 2013.

"We are pleased that, similar to our Phase 1 trial, the first external review of our Phase 2 trial data confirms that there are no safety signals that would preclude the trial from continuing as planned," said Andrew L. Pecora, M.D. FACP CPE, Chief Medical Officer of NeoStem. "The PreSERVE AMI study to date indicates that multiple National Study sites are capable of acquiring the necessary volume of bone marrow to create the AMR-001 product five to seven days after an AMI in a safe and practical manner, and once created the product can be delivered and administered without a safety signal."

NeoStem management believes that cell therapy is a disruptive technology in the $50 billion worldwide regenerative medicine market. Many key opinion leaders in the scientific, medical and investment communities consider AMR-001 to be best in class. Peak annual worldwide sales of AMR-001 for this indication could exceed $1 billion based upon a conservative market penetration of its qualified target patient population. AMR-001 is protected by two issued and multiple pending U.S. patents with corresponding patent coverage in selected markets around the world. The Amorcyte AMR-001 product development program also extends to congestive heart failure (CHF). The Company is preparing to launch its CHF Phase 1 clinical trials in early 2013. The worldwide CHF patient population is estimated to be four times larger than that of AMI.

About NeoStem, Inc.

NeoStem, Inc. ("we," "NeoStem" or the "Company") continues to develop and build on its core capabilities in cell therapy to capitalize on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. Our January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") provides NeoStem with a foundation in both manufacturing and regulatory affairs expertise. We believe this expertise, coupled with our existing research capabilities and collaborations, will allow us to achieve our mission of becoming a premier cell therapy company. Our PCT subsidiary's manufacturing base is one of the few current Good Manufacturing Practices ("cGMP") facilities available for contracting in the burgeoning cell therapy industry. Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and Amorcyte is enrolling patients for a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. We also expect to begin a Phase 1 clinical trial in 2013 to investigate AMR-001's utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is engaged in collaboration with Becton-Dickinson that is exploring the earlier stage clinical development of a T-cell therapy for autoimmune conditions. In addition, our pre-clinical assets include our VSELTM Technology platform as well as our MSC (mesenchymal stem cells) product candidate for regenerative medicine.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its CDMO business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward-looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including but not limited to (i) the Company's ability to manage its business despite operating losses and cash outflows, (ii) its ability to obtain sufficient capital or strategic business arrangement to fund its operations, including the clinical trials for AMR-001, (iii) successful results of the Company's clinical trials of AMR-001 and other cellular therapeutic products that may be pursued, (iv) demand for and market acceptance of AMR-001 or other cell therapies if clinical trials are successful and the Company is permitted to market such products, (v) establishment of a large global market for cellular-based products, (vi) the impact of competitive products and pricing, (vii) the impact of future scientific and medical developments, (viii) the Company's ability to obtain appropriate governmental licenses and approvals and, in general, future actions of regulatory bodies, including the FDA and foreign counterparts, (ix) reimbursement and rebate policies of government agencies and private payers, (x) the Company's ability to protect its intellectual property; (xi) the company's ability to successfully divest its interest in Erye, and (xii) matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

View original post here:
NeoStem Reports Data Safety Monitoring Board Recommends Continuation of PreSERVE AMI Phase 2 Trial

To Read More: NeoStem Reports Data Safety Monitoring Board Recommends Continuation of PreSERVE AMI Phase 2 Trial
categoriaUncategorized commentoComments Off on NeoStem Reports Data Safety Monitoring Board Recommends Continuation of PreSERVE AMI Phase 2 Trial | dataAugust 16th, 2012
Read All

Fresh cell therapy promises better health, sex and more

By Dr. Matthew Watson

MANILA, Philippines Celebrity hairstylist Ricky Reyes, talent manager and host Lolit Solis, actress Lorna Tolentino and even former President Joseph Estrada are only among the prominent Filipinos who swear by the healing effects of fresh cell therapy, which involves the injection of live animal cells into the body.

Reyes, who used to suffer from a rare disease which he called reading eye epilepsy, said he went to Germany last June for fresh cell therapy.

After a number of sessions, the celebrity hairstylist can now read newspapers without suffering a seizure.

It was gone immediately, he said. Pati arthritis ko. Naalis yung sakit, tapos gaganda at babata ka pa.

Solis, 65, had fresh cell therapy after experiencing knee pain, and 75-year-old Estrada opted to undergo the procedure in Germany to keep healthy.

Before them, several other well-known figures worldwide are said to have tried fresh cell treatments, among them the late English actor Charlie Chaplin.

So how is this procedure done? Dr. Robert Janson-Muller, who runs a fresh cell therapy clinic in Germany, is in town to give Filipinos the lowdown on this decades-long treatment.

Not stem cell treatment

Before starting his lecture for members of the local media on Tuesday, Janson-Muller made it clear that fresh cell therapy is different from the now controversial stem cell treatment, which aims to replace damaged organs in the body or create one from scratch.

He stressed that his methods, which do not promise miracles, have been proven effective by his predecessors for the past 60 years.

See the article here:
Fresh cell therapy promises better health, sex and more

To Read More: Fresh cell therapy promises better health, sex and more
categoriaUncategorized commentoComments Off on Fresh cell therapy promises better health, sex and more | dataAugust 14th, 2012
Read All

Everyone At Risk From Mad Cow Disease

By Dr. Matthew Watson

By John von Radowitz, Science Correspondent, PA News

No one is immune to the human form of mad cow disease, variant CJD, new research suggests today.

Some people whose genetic make-up normally acts as a barrier against infection may ultimately develop a different and so-far unrecognised type of disease, it is claimed.

Scientists have shown that individuals with a pair of genes known as MM about a third of the population acquire vCJD relatively easily.

No one with a different paring, VV, has been known to suffer the disease.

Then in August it emerged that a patient from a mixed MV genetic group had been infected with vCJD from contaminated blood, without showing any symptoms. Just over half the population has the MV pairing.

The news sparked fears of a mad cow disease timebomb in the population, with thousands of people unwittingly carrying the brain disease on a long incubation fuse. Read more…

Source:
http://feeds.feedburner.com/integratedmedicine

To Read More: Everyone At Risk From Mad Cow Disease
categoriaIntegrative Medicine commentoComments Off on Everyone At Risk From Mad Cow Disease | dataAugust 12th, 2012
Read All

Is the cell therapy sector outperforming the major indices?

By Dr. Matthew Watson


So here's what I did today.  I built a portfolio of public companies focused exclusively or predominately in the cell therapy space.  I excluded any companies that are in the sector but their products/services constitute less than a significant majority of their revenue and/or expenses.  The portfolio sits at 29 companies.  Here's the list:


Here's how the portfolio performs against the Dow Jones, Standard and Poor's, and NASDAQ indices so far this year.


When looking at the period 1 January 2012 to 10 August 2012, the cell therapy portfolio is up 42%, Dow Jones up 8%, Standard and Poor's up 12% and NASDAQ up 16%.

In the context of how much we hear about how harsh this sector is or has been on investors, I found today's analysis interesting and, honestly, pleasantly surprising.

This snapshot is useful but has its limitations. I'm relying on Google Finance for accuracy of the information provided.  Do your own due diligence. Invest accordingly.  I hope this helps.

--Lee

This snapshot has been brought to you by Cell Therapy Group: all cell therapy, all the time! 🙂

Source:
http://feeds.feedburner.com/CellTherapyBlog

To Read More: Is the cell therapy sector outperforming the major indices?
categoriaRegenerative Medicine commentoComments Off on Is the cell therapy sector outperforming the major indices? | dataAugust 12th, 2012
Read All

Researcher Alert: Opportunity for Fresh Appeal in $243 Million Disease Team Round

By Dr. Matthew Watson


A tiny opening exists for scientists
who failed to win approval last month of their bids for $20 million
research awards from the California stem cell agency.

On July 26, the agency's governing
board okayed $151 million for eight scientists during a day filled
with emotional testimony from patients, as well as appeals by
researchers seeking reconsideration of rejection by grant reviewers
at the California Institute for Regenerative Medicine. The board also
asked reviewers to take a fresh look at five applications in its signature disease team round.
However, the board failed to act on
eight applications, meaning that they are still pending. Normally the
board will approve -- as a group -- one set of applications. Then, at
the same meeting, it will vote to reject another set of applications.
On July 26, however, the hard-pressed directors late in the
afternoon lost the supermajority quorum (65 percent) required to do
business and adjourned without acting on all the applications.
This situation rarely occurs on award
rounds. In our recollection, it has happened only once before
although there may have been other occasions.
That leaves an opening for more
researchers to ask the board to act favorably at its Sept. 5-6 meeting in San Francisco on applications rejected by reviewers. Money
is available. The July 26 round was budgeted for $243 million.
At the meeting last month, discussion
by directors provided several clues to appropriate avenues for
reconsideration. They were interested in appeals, formally called
extraordinary petitions, that brought genuinely new information to
the table. Serious errors in the reviews – something more than
differences of opinion – were of interest. Wide variance in the
spread of scientific scores on specific applications, including the
preliminary scores, also triggered directors' interest.
Researchers considering appeals would
be well-advised to listen to the audiocast of the meeting to hear the
discussion of appeals. The transcript of the meeting also should be
posted soon on the CIRM website, probably this week. The transcript
can be found via this page when it is posted. The audiocast
instructions can be found on the July 26 meeting agenda.
(The best available information on the
CIRM web site shows a Sept. 5-6 governing board meeting. However,
that schedule also shows other two day meetings earlier this year,
which actually have turned out to be only one day.)

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

To Read More: Researcher Alert: Opportunity for Fresh Appeal in $243 Million Disease Team Round
categoriaStem Cell Therapy commentoComments Off on Researcher Alert: Opportunity for Fresh Appeal in $243 Million Disease Team Round | dataAugust 12th, 2012
Read All

TiGenix Completes Patient Enrollment in Phase IIa Rheumatoid Arthritis Study

By JoanneRUSSELL25

LEUVEN, BELGIUM and MADRID, SPAIN--(Marketwire -08/08/12)- TiGenix (EURONEXT:TIG), the European leader in cell therapy, announced today the completion of patient enrollment in the Company's Phase IIa study of Cx611, a suspension of expanded allogeneic adult stem cells, in rheumatoid arthritis. The Phase IIa clinical trial is a 53-subject, multicenter, placebo-controlled study in 3 cohorts with different dosing regimens, designed to assess safety, feasibility, tolerance, and optimal dosing. The study is being conducted at 23 centers. The Company believes that this clinical trial can set the stage not only for the further development of Cx611 in RA, but also in a wide range of other autoimmune disorders.

"In addition to the primary endpoints of safety and optimal dosing, we expect this trial to yield a first indication of the duration of the efficacy of Cx611 in this very difficult patient population: the enrolled patients have previously failed to respond to at least two biologicals," said Eduardo Bravo, CEO of TiGenix. "In the trial patients are treated with three injections of Cx611. The six-month follow-up without further dosing should provide us with a truly meaningful result. This is the most advanced stem cell therapy trial in RA in the world, and completing the enrollment on time confirms our leadership position in the field. We anticipate reporting the results of the study no later than April 2013."

About Cx611 for rheumatoid arthritisCx611 is a suspension of expanded allogeneic adult stem cells derived from human adipose (fat) tissue (expanded Adipose derived Stem Cells or 'eASCs') that is delivered through intra-venous injection for the treatment of rheumatoid arthritis. The objective of the Phase IIa trial is to determine safety, feasibility, tolerance, and optimal dosing. This multicentre, placebo-controlled study has enrolled 53 patients, divided in 3 cohorts with different dosing regimens. There are 23 centers open and the company expects the final results to be available in the first half of 2013.

About TiGenixTiGenix NV (EURONEXT:TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit http://www.tigenix.com.

Forward-looking informationThis document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.

Read more:
TiGenix Completes Patient Enrollment in Phase IIa Rheumatoid Arthritis Study

To Read More: TiGenix Completes Patient Enrollment in Phase IIa Rheumatoid Arthritis Study
categoriaUncategorized commentoComments Off on TiGenix Completes Patient Enrollment in Phase IIa Rheumatoid Arthritis Study | dataAugust 8th, 2012
Read All

Aaron Curry using stem cell therapy to help knees

By raymumme

AP

Raiders linebacker Aaron Curry isnt sure when hell be able to get back on the field, but hes pretty sure that stem cell therapy will be the thing that winds up getting him back there.

Paul Gutierrez of CSNBayArea.com reports that Curry has received the therapy on both of his knees. Bone marrow from his hips was used in the treatment and Curry told Gutierrez that it is the only thing hes tried that has helped him feel better. Curry is still working out on the side during Raiders practices and said hell only return to practice when hes fully able to help the Raiders.

My goal is to get healthy and just go out there and be violent, be fast, be a pain in the offenses butt and whatever I have to do on the defense, do it, Curry said. And do it full speed. I cant do that until my body says its ready.

The treatment has been popular with Oakland athletes. Linebacker Rolando McClain said that the treatment helped his legs feel better earlier this offseason and As pitcher Bartolo Colon has credited stem cell treatment on his shoulder with saving his baseball career.

With McClain facing a possible suspension under the Personal Conduct Policy and Oakland short on linebacking depth, the Raiders need Curry to be healthy for the start of the season.

Originally posted here:
Aaron Curry using stem cell therapy to help knees

To Read More: Aaron Curry using stem cell therapy to help knees
categoriaUncategorized commentoComments Off on Aaron Curry using stem cell therapy to help knees | dataAugust 5th, 2012
Read All

Review: The Locust’s Molecular Genetics from the Gold Standard Labs – ALARM Magazine

By Dr. Matthew Watson


ALARM Magazine
Review: The Locust's Molecular Genetics from the Gold Standard Labs
ALARM Magazine
Review: The Locust's Molecular Genetics from the Gold Standard Labs. By Scott Morrow. Tags. Anti · Gold Standard Laboratories · The Locust. Tweet. The Locust: Molecular Genetics from the Gold Standard Labs (Anti-). “Perils of Believing in Round Squares ...

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

To Read More: Review: The Locust’s Molecular Genetics from the Gold Standard Labs – ALARM Magazine
categoriaUncategorized commentoComments Off on Review: The Locust’s Molecular Genetics from the Gold Standard Labs – ALARM Magazine | dataAugust 5th, 2012
Read All

The Locust – Molecular Genetics From the Gold Standard Labs – God Is In The TV

By Dr. Matthew Watson


God Is In The TV
The Locust – Molecular Genetics From the Gold Standard Labs
God Is In The TV
Regardless of music ethics though, 'Molecular Genetics From the Gold Standard Labs' and its forty four tracks tread through what The Locust fans will have come to expect with classics such as my personal favourite, 'The Half-Eaten Sausage Would Like To ...

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

To Read More: The Locust – Molecular Genetics From the Gold Standard Labs – God Is In The TV
categoriaUncategorized commentoComments Off on The Locust – Molecular Genetics From the Gold Standard Labs – God Is In The TV | dataAugust 5th, 2012
Read All

Jeffrey Ravetch wins 2012 Sanofi – Institut Pasteur Award – The Rockefeller University Newswire

By Dr. Matthew Watson


The Rockefeller University Newswire
Jeffrey Ravetch wins 2012 Sanofi – Institut Pasteur Award
The Rockefeller University Newswire
Jeffrey V. Ravetch, head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at Rockefeller University, has been given the 2012 Sanofi – Institut Pasteur Award for discovering mechanisms by which antibodies carry out their diverse ...

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

To Read More: Jeffrey Ravetch wins 2012 Sanofi – Institut Pasteur Award – The Rockefeller University Newswire
categoriaUncategorized commentoComments Off on Jeffrey Ravetch wins 2012 Sanofi – Institut Pasteur Award – The Rockefeller University Newswire | dataAugust 5th, 2012
Read All

Unnatural Selection: Muscles, Genes and Genetic Cheats

By Dr. Matthew Watson

Take a close look at the athletes competing in this year's Summer Olympic Games in London --their musculature will tell you a lot about how they achieved their elite status. Endless hours of training and commitment to their sport played a big role in building the bodies that got them to the world's premier athletic competition. Take an even closer look--this one requires microscopy--and you'll see something else, something embedded in the genetic blueprints of these young men and women that's just as important to their success. [More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


Source:
http://rss.sciam.com/sciam/topic/gene-therapy

To Read More: Unnatural Selection: Muscles, Genes and Genetic Cheats
categoriaUncategorized commentoComments Off on Unnatural Selection: Muscles, Genes and Genetic Cheats | dataAugust 5th, 2012
Read All

Europe Nears First Approval for Gene Therapy Treatment

By Dr. Matthew Watson

From Nature magazine

[More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


Source:
http://rss.sciam.com/sciam/topic/gene-therapy

To Read More: Europe Nears First Approval for Gene Therapy Treatment
categoriaUncategorized commentoComments Off on Europe Nears First Approval for Gene Therapy Treatment | dataAugust 5th, 2012
Read All

AIDS: Genetic Clues from HIV Elite Controllers Could Lead to Better Vaccines, Cancer Treatments (preview)

By Dr. Matthew Watson

One day in early 1995 a man named bob massie walked into my office at the outpatient clinic of Massachusetts General Hospital in Boston. Massie told me he had been infected with HIV--the virus that causes AIDS--for 16 years and yet had never shown any symptoms. My physical examination confirmed he was healthy, in stark contrast to all other patients I saw that day. At that time, a new combination of drugs was being tested that would eventually slow the progressive decline in immune function that HIV caused. In 1995, however, most people who had been infected with HIV for a decade or more had already progressed to AIDS--the stage marked by the inability to fight off other pathogens. The young man standing before me had never taken anti-HIV medication and strongly believed that if I learned the secret to his good fortune, the information could help others to survive what was then generally thought to be a uniformly fatal disease.

[More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


Source:
http://rss.sciam.com/sciam/topic/gene-therapy

To Read More: AIDS: Genetic Clues from HIV Elite Controllers Could Lead to Better Vaccines, Cancer Treatments (preview)
categoriaUncategorized commentoComments Off on AIDS: Genetic Clues from HIV Elite Controllers Could Lead to Better Vaccines, Cancer Treatments (preview) | dataAugust 5th, 2012
Read All

Small Comfort: Nanomedicine Able to Penetrate Bodily Defenses

By Dr. Matthew Watson

Tears and a runny nose can be unpleasant on a windy day, but these mucosal secretions play a vital role in protecting the body from viruses and other malicious microbes. Unfortunately, mucus is also adept at washing away medication designed to treat infections and inflammation that occur when an infectious agent is successful in penetrating the body's defenses [More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


Source:
http://rss.sciam.com/sciam/topic/gene-therapy

To Read More: Small Comfort: Nanomedicine Able to Penetrate Bodily Defenses
categoriaUncategorized commentoComments Off on Small Comfort: Nanomedicine Able to Penetrate Bodily Defenses | dataAugust 5th, 2012
Read All

Stem Cell Blowback from Proposition 71

By Dr. Matthew Watson


Proposition 71 last week once again
stood in the way of action by the $3 billion California stem cell
agency.

This time it was a bit of minutia
embedded in state law that prevented the agency's governing board
from going forward. The result is that the board will have to hold
another meeting in August to approve matters that need to be acted on
in a timely fashion.
The minutia involves the supermajority
quorum requirement for the board, the percentage of board members
needed to conduct business legally. Proposition 71, the 10,000-word
ballot initiative that created the agency in 2004, stipulates that 65
percent of the 29 members of the board be present for action.
Here is what happened: Late last
Thursday afternoon, CIRM directors were moving fast after a long day
of dealing with $151 million in research awards. But as they
attempted to act on proposed changes in the agency's important
intellectual property rules, one of the board members left the
meeting, presumably to catch a flight. The result was that the
meeting quickly ended after it was decided to deal with the IP
proposal and another matter during a telephonic meeting this month.
The quorum problem has plagued the CIRM
board since its inception, although the situation has eased since
J.T. Thomas
, a Los Angeles bond financier, was elected chairman in
2011. A few years back, the board also changed its rules to allow a
limited number of board members to participate in meetings by
telephone, reducing the pressure on board members to physically
attend meetings.
The obvious solution would be to change
the quorum to 50 percent, a reasonable standard. However, the board
is legally barred from doing that. To make the change would require a super, supermajority vote, 70 percent of
each house of the state legislature and the signature of the
governor. That is another bit that is embedded in state law, courtesy of Proposition 71. To attempt to win a  70 percent legislative vote would involve a political process
that could be contentious and also involve some horse-trading that
the stem cell agency would not like to see.
Why does the 65-percent quorum
requirement exist? Normally, one would think such internal matters
are best left to the governing board itself. It is difficult to know
why former CIRM Chairman Bob Klein and his associates wrote that
requirement into law. But it does allow a minority to have effective
veto power over many actions by the governing board.
Of course, there is another way to look
at the problem: CIRM board members could change their flights and
stick around until all the business is done. But that would ignore
the reality that all of them are extremely busy people and have
schedules that are more than full.
All of this goes to one of the major policy issues in California -- ballot box budgeting and the use of initiatives that are inflexible and all but impossible to change, even when the state is in the midst of a financial crisis in which the poor, the elderly and school children are the victims. One California economist has called the situation "our special hell."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

To Read More: Stem Cell Blowback from Proposition 71
categoriaStem Cell Therapy commentoComments Off on Stem Cell Blowback from Proposition 71 | dataAugust 5th, 2012
Read All

$20 Million in Stem Cell Irony

By Dr. Matthew Watson


A bit of irony popped up this
week in the wake of approval of $151 million in awards by the
California stem cell agency.

One of the awards was $20 million to
StemCells, Inc., of Newark, Ca., which is also fighting hard for
another $20 million from the state research enterprise.
However, back in 2008, Kenneth
Stratton
, general counsel for the firm, put some distance between his
company and the agency, which is handing out $3 billion in toto.
Stratton said,

"We will take CIRM money last. We
don't want to be in a position where, years from now, we are actually
forced to sell [our products] in California at a loss."

But last week, Martin McGlynn, CEO of
StemCells, said in a press release,

“We are extremely grateful to CIRM
for its support.”

Times have changed for both the company
and CIRM, which is in the process of altering the intellectual
property rules that offended Stratton in 2008. The changes were due
to be approved last Thursday, but action was put off by the CIRM
board. It was overwhelmed as it dealt with the record pace of appeals
by researchers who were scrambling to overturn negative decisions by
grant reviewers.
StemCells' application for another $20
million is one of those being appealed. The board will take it up
again in either September or late October, after it undergoes
additional scrutiny by the agency.
CIRM is touting its IP changes as being
more friendly to business. They also can be made retroactive to cover
awards to business made in the past. CIRM directors expect to meet by
telephone, probably in August, to approve the new IP rules.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

To Read More: $20 Million in Stem Cell Irony
categoriaStem Cell Therapy commentoComments Off on $20 Million in Stem Cell Irony | dataAugust 5th, 2012
Read All

EDC Relocates to Barnes Center; Clients will Benefit in Clarion – Gant Daily

By Dr. Matthew Watson


Gant Daily
EDC Relocates to Barnes Center; Clients will Benefit in Clarion
Gant Daily
Representatives of Clarion University and its Small Business Development Center gather with the leadership of Clarion County Economic Development Corporation to celebrate CCEDC's relocation at Gregory Barnes Center for Biotechnology and Business ...

Source:
http://news.google.com/news?q=biotechnology&output=rss

To Read More: EDC Relocates to Barnes Center; Clients will Benefit in Clarion – Gant Daily
categoriaUncategorized commentoComments Off on EDC Relocates to Barnes Center; Clients will Benefit in Clarion – Gant Daily | dataAugust 5th, 2012
Read All

Fears over 'stem cell tourism' Save

By Dr. Matthew Watson

Aug. 5, 2012, 3 a.m.

A GROWING number of overseas clinics touting stem cell therapy for conditions ranging from sexual disorders to HIV are targeting Australia, where such treatments are restricted.

Australian scientists have raised concerns about so-called ''stem cell tourism'', saying many of the treatments offered are unproven, untested and potentially deadly.

The Swiss firm Fetal Cell Technologies International has been advertising in Australia since last year and Emcell, based in Ukraine, started promoting its services last month.

It is estimated as many as 200 Australians have travelled overseas for the therapy. The secretary for science policy at the Australian Academy of Science, Bob Williamson, said he empathised with the desperation of seriously ill people but warned against the unproven therapies, which can cost up to $60,000.

''The therapies are almost all untested and unproven and sometimes they have killed people,'' Professor Williamson said. The Sun-Herald's calls to Emcell's Melbourne office were not returned.

Stem Cells Australia's Megan Munsie, who is conducting a study into stem cell tourism with Monash University, said many people she interviewed were unaware of the risks of therapy overseas.

''We're not talking about rubbing something into your skin or taking a capsule, we are talking about often a very invasive procedure,'' she said.

See original here:
Fears over 'stem cell tourism' Save

To Read More: Fears over 'stem cell tourism' Save
categoriaUncategorized commentoComments Off on Fears over 'stem cell tourism' Save | dataAugust 4th, 2012
Read All

Fears over 'stem cell tourism'

By daniellenierenberg

A GROWING number of overseas clinics touting stem cell therapy for conditions ranging from sexual disorders to HIV are targeting Australia, where such treatments are restricted.

Australian scientists have raised concerns about so-called ''stem cell tourism'', saying many of the treatments offered are unproven, untested and potentially deadly.

The Swiss firm Fetal Cell Technologies International has been advertising in Australia since last year and Emcell, based in Ukraine, started promoting its services last month.

It is estimated as many as 200 Australians have travelled overseas for the therapy. The secretary for science policy at the Australian Academy of Science, Bob Williamson, said he empathised with the desperation of seriously ill people but warned against the unproven therapies, which can cost up to $60,000.

Advertisement

''The therapies are almost all untested and unproven and sometimes they have killed people,'' Professor Williamson said. The Sun-Herald's calls to Emcell's Melbourne office were not returned.

Stem Cells Australia's Megan Munsie, who is conducting a study into stem cell tourism with Monash University, said many people she interviewed were unaware of the risks of therapy overseas.

''We're not talking about rubbing something into your skin or taking a capsule, we are talking about often a very invasive procedure,'' she said.

See the rest here:
Fears over 'stem cell tourism'

To Read More: Fears over 'stem cell tourism'
categoriaUncategorized commentoComments Off on Fears over 'stem cell tourism' | dataAugust 4th, 2012
Read All

Annabelle to undergo stem cell therapy

By LizaAVILA

MANILA, Philippines Talent manager Annabelle Rama revealed that she will be undergoing stem cell therapy in September.

She confirmed this report to The Philippine Stars entertainment columnist Ricky Lo.

Rama said shes been suffering from several illnesses and that stem cell therapy may help make her feel better.

Im suffering from high-blood pressure, high-blood sugar and other ailments and from what I heard, after the therapy I would feel better. Lahat daw yon gagaling, she said.

Rama said her son Richard Gutierrez, who will be paying for the whole procedure, also urged her to have her back problem checked.

Richard wants me to have my scoliosis checked and my lumbar region which are giving me so much pain. So I will have two more injections for that, each costing an extra one thousand euros, she said.

Lo said in his article that the whole package, which will include nine injections, will cost around P1 million.

Meanwhile, although she earlier vented on Twitter her disappointment that her family is against her plan to run for Congress, it seems that her children have changed their mind about politics.

Rama said she is hoping that she will feel renewed after her upcoming stem cell therapy so she will be ready to file her certificate of candidacy as a Cebu congresswoman when she comes back.

Richard and my other children want me to be physically fit for the campaign, Rama said.

See the rest here:
Annabelle to undergo stem cell therapy

To Read More: Annabelle to undergo stem cell therapy
categoriaUncategorized commentoComments Off on Annabelle to undergo stem cell therapy | dataJuly 31st, 2012
Read All

Page 613«..1020..612613614615..620630..»


Copyright :: 2024